These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 27728929)

  • 21. [Assessment of bone quality. Bone quality of steroid-induced osteoporosis].
    Li M; Saito T; Amizuka N
    Clin Calcium; 2008 Mar; 18(3):328-35. PubMed ID: 18310820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Secondary osteoporosis. Glucocorticoid excess-related osteoporosis.].
    Yamauchi M
    Clin Calcium; 2018; 28(12):1635-1640. PubMed ID: 30487328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severe kyphosis secondary to glucocorticoid-induced osteoporosis in a young adult with Cushing's disease. A case report and literature review.
    Freehill AK; Lenke LG
    Spine (Phila Pa 1976); 1999 Jan; 24(2):189-93. PubMed ID: 9926392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adrenal incidentalomas and subclinical Cushing's syndrome: is there evidence for glucocorticoid-induced osteoporosis?
    Angeli A; Osella G; Reimondo G; Terzolo M
    Front Horm Res; 2002; 30():73-85. PubMed ID: 11892272
    [No Abstract]   [Full Text] [Related]  

  • 25. TXNIP is highly regulated in bone biopsies from patients with endogenous Cushing's syndrome and related to bone turnover.
    Lekva T; Ueland T; Bøyum H; Evang JA; Godang K; Bollerslev J
    Eur J Endocrinol; 2012 Jun; 166(6):1039-48. PubMed ID: 22450549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of chronic in vivo glucocorticoid excess on the functional characteristics of human skin fibroblasts obtained from patients with endogenous Cushing's syndrome.
    Zervolea I; Pratsinis H; Tsagarakis S; Karavitaki N; Stathakos D; Thalassinos N; Kletsas D
    Eur J Endocrinol; 2005 Jun; 152(6):895-902. PubMed ID: 15941930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucocorticoid-induced osteoporosis: from basic mechanisms to clinical aspects.
    Alesci S; De Martino MU; Ilias I; Gold PW; Chrousos GP
    Neuroimmunomodulation; 2005; 12(1):1-19. PubMed ID: 15756049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cushing's syndrome, glucocorticoids and the kidney.
    Smets P; Meyer E; Maddens B; Daminet S
    Gen Comp Endocrinol; 2010 Oct; 169(1):1-10. PubMed ID: 20655918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Action of glucocorticoid on bone-forming and bone-resorbing cells].
    Hakeda Y
    Clin Calcium; 2006 Nov; 16(11):1817-22. PubMed ID: 17079848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histomorphometric analysis of glucocorticoid-induced osteoporosis.
    Dalle Carbonare L; Bertoldo F; Valenti MT; Zenari S; Zanatta M; Sella S; Giannini S; Cascio VL
    Micron; 2005; 36(7-8):645-52. PubMed ID: 16243531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Corticosteroid-induced osteoporosis: pathogenesis and prevention.
    Benvenuti S; Brandi ML
    Clin Exp Rheumatol; 2000; 18(4 Suppl 20):S64-6. PubMed ID: 10948768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucocorticoids and Bone: Consequences of Endogenous and Exogenous Excess and Replacement Therapy.
    Hardy RS; Zhou H; Seibel MJ; Cooper MS
    Endocr Rev; 2018 Oct; 39(5):519-548. PubMed ID: 29905835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osteogenic growth peptide effects on primary human osteoblast cultures: potential relevance for the treatment of glucocorticoid-induced osteoporosis.
    Spreafico A; Frediani B; Capperucci C; Leonini A; Gambera D; Ferrata P; Rosini S; Di Stefano A; Galeazzi M; Marcolongo R
    J Cell Biochem; 2006 Jul; 98(4):1007-20. PubMed ID: 16795077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Functional mechanism of glucocorticoid in bone turnover and bone structure].
    Ikeda S; Akahoshi S; Sakai A; Nakamura T
    Clin Calcium; 2006 Nov; 16(11):1805-11. PubMed ID: 17079846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical deterioration of 4 of 5 cases of Cushing's syndrome after administration of STC 407].
    Köbberling J; zur Mühlen A von ; Hüfner M
    Acta Endocrinol Suppl (Copenh); 1971; 152():92. PubMed ID: 5313716
    [No Abstract]   [Full Text] [Related]  

  • 36. [New data on the pathogenesis of steroid-induced osteoporosis: consequences for therapy and prevention].
    Hüfner M; Siggelkow H
    Dtsch Med Wochenschr; 2003 Jul; 128(30):1602-8. PubMed ID: 12884149
    [No Abstract]   [Full Text] [Related]  

  • 37. Role of apoptosis in osteoporosis induced by glucocorticoids.
    Spreafico A; Frediani B; Francucci CM; Capperucci C; Chellini F; Galeazzi M
    J Endocrinol Invest; 2008 Jul; 31(7 Suppl):22-7. PubMed ID: 18791347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glucocorticoid-induced osteoporosis: an osteoblastic disease.
    Migliaccio S; Brama M; Fornari R; Greco EA; Spera G; Malavolta N
    Aging Clin Exp Res; 2007 Jun; 19(3 Suppl):5-10. PubMed ID: 18180599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Current indications for prevention and therapy of steroid-induced osteoporosis in men and women].
    Sewerynek E
    Endokrynol Pol; 2011; 62 Suppl 2():1-8. PubMed ID: 22125016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Secondary osteoporosis. Pathogenesis of glucocorticoid-induced osteoporosis].
    Takayanagi R
    Clin Calcium; 2007 Feb; 17(2):270-4. PubMed ID: 17272886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.